Cord blood banked for sickle cell: a step toward future cures
NCT ID NCT00012545
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collected umbilical cord blood from over 300 newborns with sickle cell disease, sickle cell trait, or no disease to find the best ways to process and store it. The blood is rich in stem cells that might one day be used in treatments like gene therapy or transplants. The goal was to learn how to handle cord blood from different babies so it can be ready for future therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
307 people
The number who actually took part.
- Started
-
Nov 2001
- Finished
-
Oct 2023
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
This is a pilot feasibility study for which umbilical cord blood samples will be collected and transported to the NIH Clinical Center for our developmental research. Pregnant women whose babies are at risk for sickle cell anemia will be identified and referred to the NIH Research Coordinator for evaluation and entry into the study. The NIH Research Coordinator is experienced in performing patient education and counseling concerning sickle cell disease, and obtaining informed consent.
- Ages
-
18 to 45 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: Pregnant women who are at risk of having an infant or infants (in case of multiple births) with sickle cell disease of the following types: Hemoglobin Sbeta 0 thalassemia Hemoglobin Sbeta + thalassemia Hemoglobin SC Hemoglobin SD Hemoglobin SE Hemoglobin SS Or other sickle-related variant determined acceptable by PI 1. Maternal subjects must be between 18 and 45 years old. 2. Maternal subjects must be able to provide informed consent. 3. Maternal subjects must work with their obstetrician to insure appropriate cord blood collection, sample collection, and completion of related documents. 4. Maternal subjects enrolled on other studies are not excluded, unless the other study may interfere with the present one. EXCLUSION CRITERIA: 1. The maternal subject will not be eligible for study if she is known to be positive for one or more of the following diseases transmissible by blood: HIV, hepatitis B, hepatitis C, WNV, HTLV or ZIKV. 2. Maternal subject will not be eligible for the study if she has active syphilis, toxoplasmosis, malaria or 3. Maternal subject will not be eligible for the study if the pregnancy resulted from egg donation or sperm donation. 4. Maternal subject is unable to give informed consent. 5. Maternal subject is known to have a fetus with a significant congenital anomaly, either not compatible with life, or requiring immediate surgical intervention or care in the Neonatal Intensive Care Unit. 6. Maternal subject has cancer or received treatment for cancer during pregnancy. 7. Infant is premature (\<34 weeks). 8. Maternal subject may be excluded at the time of delivery if the attending physician or collection staff deems that the cord blood collection is inadvisable, due to unanticipated obstetrical complications. 9. Cord blood received by CCBB/STLC is greater than 72 hours from collection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Sickle cell disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sickle cell clues to diabetes risk hidden in DNA
- Can adding common pain drugs reduce morphine needs in sickle cell crises?
- Gene editing offers hope for a One-Time sickle cell cure
- Tiny biochip could reveal sickle cell severity
- Can a milder transplant cure sickle cell and thalassemia in adults?
- Can an antioxidant supplement calm sickle cell blood cells?